<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012487</article-id><article-id pub-id-type="publisher-id">ACM-39516</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_84516058.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  APRI、FIB-4、RPR和GPR在慢性HBV感染诊断中的意义
  Significance of APRI, FIB-4, RPR and GPR in the Diagnosis of Chronic HBV Infection
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>严</surname><given-names>美红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>亚平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>营</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>边</surname><given-names>城</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院感染性疾病科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛市即墨区人民医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3253</fpage><lpage>3262</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：观察慢性乙型肝炎病毒(hepatitis B virus, HBV)感染自然史不同阶段血清天冬氨酸转氨酶和血小板比率指数(APRI)、肝纤维化4因子指数(FIB-4)、红细胞体积分布宽度–血小板比值(RPR)和γ-谷氨酰转肽酶–血小板比值(GPR)的变化，研究其在慢性HBV感染诊断中的意义。方法收集：2018年~2020年青岛大学附属医院、青岛传染病医院确诊的未经抗病毒治疗的慢性HBV感染肝炎患者292例及肝硬化患者88例。根据《慢性乙型肝炎防治指南》中HBV感染的自然史划分标准将慢性HBV感染肝炎患者分为4组：免疫耐受期、免疫清除期、免疫控制期和再活动期。患者均行血常规、生化学、病毒学及影像学检查，计算APRI、FIB-4、GPR和RPR指数，对APRI、FIB-4、GPR和RPR四种无创诊断模型与慢性HBV感染疾病进展的相关性检验进行Spearman相关分析，采用受试者工作曲线(ROC曲线))评估APRI、FIB-4、GPR和RPR指数对慢性HBV感染病程的诊断价值。结果：APRI、FIB-4、GPR、RPR指数与HBV感染疾病进程呈正相关，相关系数分别是0.306、0.433、0.133、0.439，P均 &lt; 0.05。其中APRI在诊断免疫清除期及再活动期时的曲线下面积最高，ARROC分别为0.939、0.956。在诊断肝硬化时FIB-4的曲线下面积高于APRI，AUROC分别为0.817。结论：APRI和FIB-4对慢性HBV感染者病程分期具有较好的诊断价值，APRI值及FIB-4可作为无创性评估HBV感染疾病进展的优选指标，但不能代替肝活检检查。
    Aim: To observe the changes of serum aspartate aminotransferase and platelet ratio index (APRI), liver fibrosis factor 4 index (FIB-4), red blood cell volume distribution width platelet ratio (RPR) and gamma glutamyl transpeptidase platelet ratio (GPR) in different stages of the natural history of chronic hepatitis B virus infection. Methods: From 2013 to 2020, 292 patients with chronic HBV infection and 88 patients with liver cirrhosis who were diagnosed in Qingdao University Hospital and Qingdao Infectious Disease Hospital without antiviral treatment were collected. According to the natural history classification criteria of HBV infection in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B”: Patients with chronic HBV infection are divided into 4 groups: immune tolerance period, immune clearance period, immune control period and reactivation period. All patients underwent blood routine, biochemical, virological and imaging examinations, and calculated APRI, FIB-4, GPR and RPR indexes. The four non-invasive diagnostic models of APRI, FIB-4, GPR and RPR and the progression of chronic HBV infection Correlation test Spearman correlation analysis was performed, and receiver operating curve (ROC curve) was used to evaluate the diagnostic value of APRI, FIB-4, GPR and RPR indexes for the course of chronic HBV infection. Results APRI, FIB-4, GPR, RPR indexes were positively correlated with the progression of HBV infection, the correlation coefficients were 0.306, 0.433, 0.133, 0.439, all P &lt; 0.05. Among them, APRI has the highest area under the curve in the diagnosis of immune clearance and reactivation, which are 0.939 and 0.956 respectively. In diagnosing liver cirrhosis, FIB-4 is higher than APRI, AUROC is 0.817. Conclusion APRI and FIB-4 have good diagnostic value for the stage of chronic HBV infection. APRI and FIB-4 can be used as preferred indicators for non-invasive assessment of the progression of HBV infection, but they cannot replace liver biopsy. 
  
 
</p></abstract><kwd-group><kwd>慢性HBV感染，APRI，FIB-4，GPR，RPR, Chronic HBV Infection</kwd><kwd> APRI</kwd><kwd> FIB-4</kwd><kwd> GPR</kwd><kwd> RPR</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察慢性乙型肝炎病毒(hepatitis B virus, HBV)感染自然史不同阶段血清天冬氨酸转氨酶和血小板比率指数(APRI)、肝纤维化4因子指数(FIB-4)、红细胞体积分布宽度–血小板比值(RPR)和γ-谷氨酰转肽酶–血小板比值(GPR)的变化，研究其在慢性HBV感染诊断中的意义。方法收集：2018年~2020年青岛大学附属医院、青岛传染病医院确诊的未经抗病毒治疗的慢性HBV感染肝炎患者292例及肝硬化患者88例。根据《慢性乙型肝炎防治指南》中HBV感染的自然史划分标准将慢性HBV感染肝炎患者分为4组：免疫耐受期、免疫清除期、免疫控制期和再活动期。患者均行血常规、生化学、病毒学及影像学检查，计算APRI、FIB-4、GPR和RPR指数，对APRI、FIB-4、GPR和RPR四种无创诊断模型与慢性HBV感染疾病进展的相关性检验进行Spearman相关分析，采用受试者工作曲线(ROC曲线))评估APRI、FIB-4、GPR和RPR指数对慢性HBV感染病程的诊断价值。结果：APRI、FIB-4、GPR、RPR指数与HBV感染疾病进程呈正相关，相关系数分别是0.306、0.433、0.133、0.439，P均 &lt; 0.05。其中APRI在诊断免疫清除期及再活动期时的曲线下面积最高，ARROC分别为0.939、0.956。在诊断肝硬化时FIB-4的曲线下面积高于APRI，AUROC分别为0.817。结论：APRI和FIB-4对慢性HBV感染者病程分期具有较好的诊断价值，APRI值及FIB-4可作为无创性评估HBV感染疾病进展的优选指标，但不能代替肝活检检查。</p></sec><sec id="s2"><title>关键词</title><p>慢性HBV感染，APRI，FIB-4，GPR，RPR</p></sec><sec id="s3"><title>Significance of APRI, FIB-4, RPR and GPR in the Diagnosis of Chronic HBV Infection</title><p>Meihong Yan<sup>1</sup>, Yaping Wang<sup>2</sup>, Ying Liu<sup>1</sup>, Cheng Bian<sup>1*</sup></p><p><sup>1</sup>Department of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>People’s Hospital of Jimo District, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/57-1571737x5_hanspub.png" /></p><p>Received: Nov. 27<sup>th</sup>, 2020; accepted: Dec. 23<sup>rd</sup>, 2020; published: Dec. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/57-1571737x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Aim: To observe the changes of serum aspartate aminotransferase and platelet ratio index (APRI), liver fibrosis factor 4 index (FIB-4), red blood cell volume distribution width platelet ratio (RPR) and gamma glutamyl transpeptidase platelet ratio (GPR) in different stages of the natural history of chronic hepatitis B virus infection. Methods: From 2013 to 2020, 292 patients with chronic HBV infection and 88 patients with liver cirrhosis who were diagnosed in Qingdao University Hospital and Qingdao Infectious Disease Hospital without antiviral treatment were collected. According to the natural history classification criteria of HBV infection in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B”: Patients with chronic HBV infection are divided into 4 groups: immune tolerance period, immune clearance period, immune control period and reactivation period. All patients underwent blood routine, biochemical, virological and imaging examinations, and calculated APRI, FIB-4, GPR and RPR indexes. The four non-invasive diagnostic models of APRI, FIB-4, GPR and RPR and the progression of chronic HBV infection Correlation test Spearman correlation analysis was performed, and receiver operating curve (ROC curve) was used to evaluate the diagnostic value of APRI, FIB-4, GPR and RPR indexes for the course of chronic HBV infection. Results APRI, FIB-4, GPR, RPR indexes were positively correlated with the progression of HBV infection, the correlation coefficients were 0.306, 0.433, 0.133, 0.439, all P &lt; 0.05. Among them, APRI has the highest area under the curve in the diagnosis of immune clearance and reactivation, which are 0.939 and 0.956 respectively. In diagnosing liver cirrhosis, FIB-4 is higher than APRI, AUROC is 0.817. Conclusion APRI and FIB-4 have good diagnostic value for the stage of chronic HBV infection. APRI and FIB-4 can be used as preferred indicators for non-invasive assessment of the progression of HBV infection, but they cannot replace liver biopsy.</p><p>Keywords:Chronic HBV Infection, APRI, FIB-4, GPR, RPR</p><disp-formula id="hanspub.39516-formula71"><graphic xlink:href="//html.hanspub.org/file/57-1571737x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/57-1571737x8_hanspub.png" /> <img src="//html.hanspub.org/file/57-1571737x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性乙型病毒性肝炎(Chronic hepatitis B, CHB)是我国发病率较高的传染性疾病，主要通过血液、母婴及性传播，随着病程的发展，患者肝细胞出现一定程度的损伤，从肝纤维化逐渐向前发展，最终导致肝硬化甚至肝癌的发生，对生命安全构成严重威胁 [<xref ref-type="bibr" rid="hanspub.39516-ref1">1</xref>]。乙型肝炎病毒(hepatitis B virus, HBV)是一种嗜肝性DNA病毒，慢性HBV感染者的自然病程可有免疫耐受期、免疫清除期、免疫控制期及再活动期四个阶段。有相当一部分病人可能会出现转氨酶升高的情况，但是有时并不能明确患者肝功异常是否是由HBV病毒感染导致宿主免疫激活而产生，因此如果此时抗病毒治疗可能会造成后续很多问题，如抗病毒药的副作用及停药时间等。目前，决定抗病毒治疗最有效的依据就是根据肝脏所处的炎症及肝纤维化程度，而评估肝脏炎症及肝纤维化的金标准是肝组织病理学检查。但是，肝活检容易出现抽样错误以及观察者之间和观察者之间存在较大差异，从而导致纤维化分期过高或分期不足；此外，该过程为有创性检查，还具有较高的并发症，包括感染，大出血和胆汁泄漏，甚至导致死亡 [<xref ref-type="bibr" rid="hanspub.39516-ref2">2</xref>]。因此，需要非侵入性方法来准确地诊断疾病所处的时期，特别是在决定开始抗病毒治疗时。评估慢性肝病纤维化程度不仅能评估患者病情，而且对是否启动抗病毒治疗至关重要。目前多数研究致力于无创检查评估肝脏纤维化的指标，包括实验室指标的评分模型以及基于影像学检查的肝脏弹性成像等多种无创检测手段 [<xref ref-type="bibr" rid="hanspub.39516-ref3">3</xref>]。APRI、FIB-4、GPR、RPR近年来作为用来评价肝纤维化程度的指标，很少有研究其在慢性乙型病毒性肝炎四期中的变化，因此，本研究旨在探讨慢性HBV感染者自然史不同阶段患者APRI、FIB-4、GPR、RPR的变化，分析各期患者APRI、FIB-4、RPR、GPR与病情进展的相关性，研究其在慢性HBV感染诊断中的意义，为慢性HBV感染者的疾病进展评估提供更多依据。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>收集2018年~2020年青岛大学附属医院、青岛传染病医院确诊的慢性HBV感染患者380例，根据《慢性乙型肝炎防治指南2019版》 [<xref ref-type="bibr" rid="hanspub.39516-ref1">1</xref>] 中HBV感染的自然史划分标准分为5组：免疫耐受期44例，免疫清除期109例，免疫控制期38例，再活动期66例，肝硬化组88例。纳入标准：所有患者均符合《慢性乙肝防治指南2019版》中的相关诊断标准。患者HBsAg感染超过6个月，免疫耐受期：HBsAg和HBeAg阳性，HBVDNA &gt; 2 &#215; 10<sup>7</sup> (IU/ml)，ALT正常，肝脏病理学无明显炎症坏死和纤维化；免疫清除期：HBsAg和HBeAg阳性，HBVDNA &gt; 2 &#215; 10<sup>4</sup> (IU/ml)，ALT持续或反复升高，肝脏病理学有明显炎症坏死和(或纤维化)；免疫控制期：HBsAg阳性，HBeAg阴性，HBVDNA &lt; 2000 (IU/ml)，ALT正常，肝脏病理学无或仅有轻度炎症，可有不同程度的纤维化；再活动期：HBsAg阳性，HBeAg阴性，HBVDNA ≥ 2000 (IU/ml)，ALT持续或反复升高，肝脏病理学有明显的炎症坏死和(或)纤维化。乙型肝炎肝硬化：超声、CT等影像学检查符合肝硬化表现。所有患者未经过任何抗病毒治疗。排除标准：存在甲、丙、丁、戊等及其他肝炎病毒的感染，或有自身免疫性肝病、药物性肝炎、酒精性肝炎、非酒精性脂肪性肝病、肝癌等其他原因导致的肝脏损伤。患者临床资料均经患者同意，签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 仪器与方法</title><p>采用OPUS全自动生化分析仪检测谷丙转氨酶、谷草转氨酶等生化指标。采用全自动血常规分析仪检测血小板计数、红细胞体积分布宽度。病毒学标志物(包括HBsAg，HBsAb，HBeAg，HBeAb及HBcAb)用ELISA方法测定。</p></sec><sec id="s6_3"><title>2.3. 主要检测指标</title><p>所有患者均检测血常规、肝功能、乙肝五项定量、HBVDNA及影像学检查。记录血小板计数、天冬氨酸转氨酶(aspartate aminotransferase, AST)、丙氨酸转氨(alanine aminotransferase, ALT)、γ-谷氨酰转肽酶(γ-glutamyl transpeptidase, GGT)，红细胞分布宽度(red cell volume distribution width)，计算GPR、APRI、FIB-4及RPR。计算公式：GPR = GGT (U/L)/血小板计数(&#215;10<sup>9</sup>/L)，APRI = AST (U/L)/血小板计数(&#215;10<sup>9</sup>/L)，FIB-4 = [年龄(岁) &#215; AST (U/L)]/[血小板计数(&#215;10<sup>9</sup>/L) &#215; ALT (U/L)<sup>1/2</sup>]，RPR = RDW/血小板计数 [<xref ref-type="bibr" rid="hanspub.39516-ref4">4</xref>]。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 26.0统计软件进行数据分析，计量资料符合正态分布的数据用均数 &#177; 标准差(x &#177; s)表示，不符合正态分布的数据以中位数和四分位数间[M (P25~P75)]，连续计量资料符合正态分布且方差齐者，采用独立样本T检验，非正态分布采用非参数检验(Mann-Whitney U检验)。P &lt; 0.05为差异有统计学意义。APRI、FIB-4、RPR及GPR指数与慢性HBV感染疾病进展之间的相关性采用Spearman检验。绘制受试者工作特征(receiver operating characteristic, ROC)曲线评价各指标诊断疾病进展的价值，曲线下面积(area under curve, AUC) ≥ 0.700提示诊断价值较高，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者临床资料的比较</title><p>本研究最终纳入380例患者，其中慢性HBV感染患者组免疫耐受期63例，免疫清除期104例，免疫控制期59例，再活动期66例。男145例、女147例，年龄为(42.14 &#177; 12.79)岁；肝硬化组88例，年龄为(50.93 &#177; 13.26)岁，男62例，女28例。结果发现年龄、性别、PLT、ALT、AST、RDW、GGT、AFP、ALB在慢性HBV感染各病程分期中差异具有统计学意义。进行两两比较后发现：慢性HBV感染4个时期的FIB-4、RPR、GPR与肝硬化期比较，差异均具有统计学意义。APRI除免疫清除期外，另外三期与肝硬化期比较，均具有统计学意义(P &lt; 0.05)。APRI与FIB-4两者在免疫耐受期与免疫清除期、免疫控制期与再活动期具有统计学差异(P &lt; 0.05)，GPR仅在免疫抑制期与再活动期差异具有统计学意义(P &lt; 0.05)。RPR在慢性乙型肝炎四期中均仅与肝硬化期差异具有统计学意义(P &lt; 0.05)，四期未见统计学差异(P &gt; 0.05)。结果见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic clinical data of different stages of the natural history of chronic HBV infection [M (P25 - P75)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >免疫耐受期</th><th align="center" valign="middle" >免疫清除期</th><th align="center" valign="middle" >免疫控制期</th><th align="center" valign="middle" >再活动期</th><th align="center" valign="middle" >肝硬化期</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >37.05 &#177; 11.72</td><td align="center" valign="middle" >41.91 &#177; 12.61</td><td align="center" valign="middle" >46.37 &#177; 12.88</td><td align="center" valign="middle" >44.38 &#177; 11.62</td><td align="center" valign="middle" >50.93 &#177; 13.26</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >29/34</td><td align="center" valign="middle" >61/43</td><td align="center" valign="middle" >22/37</td><td align="center" valign="middle" >33/33</td><td align="center" valign="middle" >62/28</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >PLT (&#215;10<sup>9</sup>)</td><td align="center" valign="middle" >208.82 &#177; 57.13</td><td align="center" valign="middle" >172.19 &#177; 45.17</td><td align="center" valign="middle" >211.07 &#177; 47.42</td><td align="center" valign="middle" >179.8 &#177; 45.70</td><td align="center" valign="middle" >112.77 &#177; 51.65</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >ALT (U/L)</td><td align="center" valign="middle" >26.9 (18~40.73)</td><td align="center" valign="middle" >129 (83~299)</td><td align="center" valign="middle" >21 (15~28)</td><td align="center" valign="middle" >146 (71.5~245.3)</td><td align="center" valign="middle" >68 (42~187)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >AST (U/L)</td><td align="center" valign="middle" >22.55 (18.2~28.0)</td><td align="center" valign="middle" >78 (46~158.25)</td><td align="center" valign="middle" >18.7 (15.08~22.7)</td><td align="center" valign="middle" >69 (42.3~117.3)</td><td align="center" valign="middle" >59 (32.65~125.5)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >APRI</td><td align="center" valign="middle" >0.27 (0.21~0.35)</td><td align="center" valign="middle" >1.07 (0.65~2.48)</td><td align="center" valign="middle" >0.24 (0.18~0.28)</td><td align="center" valign="middle" >0.81 (0.45~1.73)</td><td align="center" valign="middle" >1.51 (0.59~3.62)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >FIB-4</td><td align="center" valign="middle" >0.78 (0.51~1.19)</td><td align="center" valign="middle" >1.38 (0.79~2.89)</td><td align="center" valign="middle" >0.80 (0.65~1.13)</td><td align="center" valign="middle" >1.39 (0.86~2.44)</td><td align="center" valign="middle" >3.75 (1.61~7.76)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >GPR</td><td align="center" valign="middle" >0.33 (0.24~0.61)</td><td align="center" valign="middle" >0.38 (0.23~0.96)</td><td align="center" valign="middle" >0.14 (0.08~0.19)</td><td align="center" valign="middle" >0.31 (0.14~0.72)</td><td align="center" valign="middle" >0.88 (0.32~1.85)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >RPR</td><td align="center" valign="middle" >0.07 (0.05~0.17)</td><td align="center" valign="middle" >0.07 (0.06~0.09)</td><td align="center" valign="middle" >0.08 (0.06~0.17)</td><td align="center" valign="middle" >0.07 (0.06~0.09)</td><td align="center" valign="middle" >0.12 (0.09~0.21)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >RDW [CV (%)]</td><td align="center" valign="middle" >12.6 (12.2~39)</td><td align="center" valign="middle" >12.5 (12~13.18)</td><td align="center" valign="middle" >13.5 (12.4~39.8)</td><td align="center" valign="middle" >12.35 (11.9~13.1)</td><td align="center" valign="middle" >13.1 (12.4~14.55)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >GGT (U/L)</td><td align="center" valign="middle" >45 (14~63.5)</td><td align="center" valign="middle" >45 (32~108)</td><td align="center" valign="middle" >18.1 (13~25.1)</td><td align="center" valign="middle" >43.5 (24.75~78)</td><td align="center" valign="middle" >53.3 (34.9~91)</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >ALB (g/l)</td><td align="center" valign="middle" >44.135 (41.1~46.96)</td><td align="center" valign="middle" >41.1 (38.55~44.65)</td><td align="center" valign="middle" >43.69 (41.5~45.90)</td><td align="center" valign="middle" >44.1 (41.33~46.45)</td><td align="center" valign="middle" >38.41 (31.87~42.1)</td><td align="center" valign="middle" >0.00</td></tr></tbody></table></table-wrap><p>表1. 慢性HBV感染者自然史不同阶段的临床基本资料[M (P25~P75)]</p></sec><sec id="s7_2"><title>3.2. APRI、FIB-4、GPR、RPR与慢性HBV感染疾病进展的相关性分析</title><p>经Spearman相关性分析显示，APRI、FIB-4、GPR、RPR指数与慢性HBV感染疾病进展均呈正相关，相关系数分别是0.336、0.423、0.165、0.264，P均 &lt; 0.05。结果见图1。</p><p>图1. 患者APRI、FIB-4、RPR、GPR与病情进展的相关性</p></sec><sec id="s7_3"><title>3.3. APRI、FIB-4、GPR、RPR对各病程分期的诊断价值</title><p>通过ROC曲线处理显示，APRI、FIB-4、RPR均对慢性HBV感染各病程具有一定的诊断价值。其中APRI诊断免疫清除期与再活动期的效能最高，曲线下面积分别是0.950、0.951；FIB-4对肝硬化期的诊断效能最高，AUC为0.817。RPR在肝炎病程诊断中未表现出良好的诊断价值(P &gt; 0.05)。APRI、FIB-4、GPR均对免疫清除期具有相对较高的诊断价值，从高到底依次为APRI、FIB-4、RPR，诊断免疫清除期的AUC分别是0.950、0.733、0.612。其中APRI的诊断效能最高，其AUC为0.950，95% CI (0.919~0.980)，敏感度及特异度也最高(见表2，图2(A))。GPR的AUC为0.494，P &gt; 0.05，对免疫清除期无诊断意义。再活动期，APRI的诊断效能最高，其AUC为0.951，95% CI (0.915~0.988)，敏感度及特异度也较高，即其对CHB患者再活动期诊断的误诊率和漏诊率较低(见表3，图2(B))。在诊断肝硬化期时，FIB-4的诊断效能最高，其AUC为0.817，95% CI为(0.766~0.869)，其敏感度最高，即其对CHB感染的肝硬化期的漏诊率最低，特异度为0.662，对CHB感染的肝硬化期的存在一定的漏诊率(见表4，图2(C))。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The diagnostic value of APRI, FIB-4, GPR, RPR in the immune clearance period of chronic HBV infectio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >诊断模型</th><th align="center" valign="middle" >AUC</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >敏感度</th><th align="center" valign="middle" >特异度</th><th align="center" valign="middle" >截断值</th><th align="center" valign="middle" >约登指数</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >APRI</td><td align="center" valign="middle" >0.950</td><td align="center" valign="middle" >0.919~0.980</td><td align="center" valign="middle" >0.835</td><td align="center" valign="middle" >0.937</td><td align="center" valign="middle" >0.569</td><td align="center" valign="middle" >0.772</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >FIB-4</td><td align="center" valign="middle" >0.733</td><td align="center" valign="middle" >0.658~0.808</td><td align="center" valign="middle" >0.573</td><td align="center" valign="middle" >0.81</td><td align="center" valign="middle" >1.258</td><td align="center" valign="middle" >0.383</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >GPR</td><td align="center" valign="middle" >0.612</td><td align="center" valign="middle" >0.527~0.698</td><td align="center" valign="middle" >0.587</td><td align="center" valign="middle" >0.727</td><td align="center" valign="middle" >0.888</td><td align="center" valign="middle" >0.222</td><td align="center" valign="middle" >0.015</td></tr><tr><td align="center" valign="middle" >RPR</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.391~0.596</td><td align="center" valign="middle" >0.816</td><td align="center" valign="middle" >0.365</td><td align="center" valign="middle" >0.058</td><td align="center" valign="middle" >0.181</td><td align="center" valign="middle" >0.893</td></tr></tbody></table></table-wrap><p>表2. APRI、FIB-4、GPR、RPR对慢性HBV感染免疫清除期的诊断价值</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The diagnostic value of APRI, FIB-4, GPR, RPR in the reactivation stage of chronic HBV infectio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >诊断模型</th><th align="center" valign="middle" >AUC</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >敏感度</th><th align="center" valign="middle" >特异度</th><th align="center" valign="middle" >截断值</th><th align="center" valign="middle" >约登指数</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >APRI</td><td align="center" valign="middle" >0.951</td><td align="center" valign="middle" >0.915~0.988</td><td align="center" valign="middle" >0.855</td><td align="center" valign="middle" >0.949</td><td align="center" valign="middle" >0.422</td><td align="center" valign="middle" >0.804</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >FIB-4</td><td align="center" valign="middle" >0.715</td><td align="center" valign="middle" >0.624~0.806</td><td align="center" valign="middle" >0.645</td><td align="center" valign="middle" >0.729</td><td align="center" valign="middle" >1.050</td><td align="center" valign="middle" >0.374</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >GPR</td><td align="center" valign="middle" >0.758</td><td align="center" valign="middle" >0.666~0.850</td><td align="center" valign="middle" >0.645</td><td align="center" valign="middle" >0.881</td><td align="center" valign="middle" >0.241</td><td align="center" valign="middle" >0.526</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >RPR</td><td align="center" valign="middle" >0.393</td><td align="center" valign="middle" >0.293~0.503</td><td align="center" valign="middle" >0.887</td><td align="center" valign="middle" >0.169</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.056</td><td align="center" valign="middle" >0.053</td></tr></tbody></table></table-wrap><p>表3. APRI、FIB-4、GPR、RPR对慢性HBV感染再活动期的诊断价值</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The diagnostic value of APRI, FIB-4, GPR, RPR in the stage of liver cirrhosi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >诊断模型</th><th align="center" valign="middle" >AUC</th><th align="center" valign="middle" >95% CI</th><th align="center" valign="middle" >敏感度</th><th align="center" valign="middle" >特异度</th><th align="center" valign="middle" >截断值</th><th align="center" valign="middle" >约登指数</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >APRI</td><td align="center" valign="middle" >0.743</td><td align="center" valign="middle" >0.688~0.798</td><td align="center" valign="middle" >0.651</td><td align="center" valign="middle" >0.732</td><td align="center" valign="middle" >1.059</td><td align="center" valign="middle" >0.383</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >FIB-4</td><td align="center" valign="middle" >0.817</td><td align="center" valign="middle" >0.766~0.869</td><td align="center" valign="middle" >0.831</td><td align="center" valign="middle" >0.662</td><td align="center" valign="middle" >1.411</td><td align="center" valign="middle" >0.493</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >GPR</td><td align="center" valign="middle" >0.703</td><td align="center" valign="middle" >0.632~0.773</td><td align="center" valign="middle" >0.614</td><td align="center" valign="middle" >0.753</td><td align="center" valign="middle" >0.611</td><td align="center" valign="middle" >0.367</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >RPR</td><td align="center" valign="middle" >0.762</td><td align="center" valign="middle" >0.709~0.816</td><td align="center" valign="middle" >0.807</td><td align="center" valign="middle" >0.638</td><td align="center" valign="middle" >0.084</td><td align="center" valign="middle" >0.445</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表4. APRI、FIB-4、GPR、RPR对肝硬化期的诊断价值</p><p>图2. APRI、FIB-4、GPR、RPR对慢性HBV感染免疫清除期、再活动期和肝硬化期的诊断价值。(A) 诊断免疫清除期的ROC曲线；(B) 诊断再活动期的ROC曲线；(C) 诊断肝硬化期的ROC曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>慢性HBV感染仍然是全球性的公共卫生问题，目前全世界感染乙型肝炎病毒的人数达到了2.9亿人 [<xref ref-type="bibr" rid="hanspub.39516-ref5">5</xref>]，如果不能及时的治疗，则有20%的CHB感染者会死于肝硬化、肝衰竭甚至肝细胞癌 [<xref ref-type="bibr" rid="hanspub.39516-ref6">6</xref>]。慢性乙型病毒性感染后，分为免疫耐受期、免疫清除期、免疫控制期及再活动期。HBV感染后的自然病程十分复杂，与病毒量、宿主免疫条件及环境都存在一定关系。慢性HBV感染自然史是肝脏炎症及纤维化程度进行性加重的过程，尽管在免疫耐受期及免疫控制期，机体免疫与HBV病毒能够“和谐相处”，肝脏病理无明显疾病进展，但是一旦宿主免疫激活，不论是免疫清除期时宿主免疫过强对HBV病毒的清除，或是宿主免疫过弱造成HBV病毒造成大量复制，最终结果都是肝脏持续出现炎症，肝组织学检查有明显的炎症坏死和(或)纤维化，最终导致肝硬化甚至肝癌的发生。尽管有研究表明长时间的抗病毒治疗在一定程度上能够组织病理学得到改善甚至逆转肝纤维化 [<xref ref-type="bibr" rid="hanspub.39516-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39516-ref8">8</xref>]，但是随着肝纤维化程度的进展，如果没有得到及时的治疗，恐怕难以达到肝纤维化的逆转 [<xref ref-type="bibr" rid="hanspub.39516-ref9">9</xref>]。因此，准确判断肝脏纤维化是有效管理CHB患者的关键，对于疾病的进展尤为重要。目前肝组织病理学检查仍然是评估肝脏组织病理状态、诊断肝纤维化的金标准 [<xref ref-type="bibr" rid="hanspub.39516-ref10">10</xref>]，但是由于其为有创检查，存在出血、感染等并发症及可操作性差等原因 [<xref ref-type="bibr" rid="hanspub.39516-ref11">11</xref>]，不能广泛应用于评估及动态监测肝纤维化进展。因此无创诊断肝纤维化越来越被临床大夫所接受。有研究指出，APRI和 FIB-4是诊断慢性乙型肝炎患者显著纤维化和肝硬化的合适诊断模型 [<xref ref-type="bibr" rid="hanspub.39516-ref12">12</xref>]，2019年《慢性乙型肝炎防治指南》 [<xref ref-type="bibr" rid="hanspub.39516-ref4">4</xref>] 中也指出二者可以作为评估肝纤维化的一种无创诊断。RPR在诊断慢性乙型肝炎尤其是显著肝纤维化及肝硬化期具有一定的诊断效能 [<xref ref-type="bibr" rid="hanspub.39516-ref13">13</xref>]。有研究表示在中国人群中GPR模型对预测CHB患者肝纤维化的诊断价值要优于APRI和FIB-4模型，并随着肝纤维化程度诊断效能越高 [<xref ref-type="bibr" rid="hanspub.39516-ref14">14</xref>]，Lemoine [<xref ref-type="bibr" rid="hanspub.39516-ref15">15</xref>] 等创立的GPR模型对预测评估西非地区CHB患者显著肝纤维化的诊断价值要优于APRI和FIB-4模型，而在法国对明显肝纤维化的诊断价值却与APRI、FIB-4模型相当。APRI、FIB-4、RPR、GPR是基于血清学指标的肝纤维化评估模型，具有经济简便的特点，在临床上也得到了应用，尤其是在卫生资源不足的地区，可以作为肝纤维化的筛查指标。本研究结果显示APRI、FIB-4在免疫清除期及再活动期明显高于免疫耐受期与免疫抑制期，表明随着机体免疫系统的激活，HBV病毒在肝脏内活动，造成机体各种免疫细胞、细胞因子、介质等的参与，造成肝细胞的损伤，肝脏炎症活动度增加，并且肝脏炎症程度与肝纤维化程度存在一定的相关性 [<xref ref-type="bibr" rid="hanspub.39516-ref16">16</xref>]，表明免疫清除期、再活动期的肝纤维化程度明显高于免疫抑制期及免疫耐受期，这与廖等 [<xref ref-type="bibr" rid="hanspub.39516-ref17">17</xref>] 基于肝活检的结果一致。有研究表明RPR在显著纤维化及肝硬化期能够表现出一定的诊断价值 [<xref ref-type="bibr" rid="hanspub.39516-ref13">13</xref>]，与本研究中RPR结果所示的肝炎四期肝纤维化程度未见明显差异，而肝硬化期的肝纤维化程度明显高于慢性乙型病毒性肝炎期的纤维化程度一致。APRI、GPR在肝硬化期高于免疫清除期，但免疫清除期与肝硬化期未见明显差异，可能一部分处于免疫清除期的慢性HBV感染的肝脏纤维化程度较重，已达到显著肝纤维化甚至肝硬化的阶段，有研究显示慢性乙型病毒性肝炎期存在相当一部分患者已达到F2期及以上，这与本研究结果类似。本研究显示，APRI、FIB-4、GPR、RPR指数与慢性HBV感染疾病进展均呈正相关，表明其与HBV感染的疾病进展具有相关性。其中FIB-4、APRI的相关系数相对较高，又以FIB-4的相关系数最高，但其相关系数均小于0.5，与疾病进展呈弱相关。本研究中，APRI、FIB-4在预测免疫清除期时的AUROC数值达到了0.7以上，APRI甚至达到了0.9以上，明显高于FIB-4，且其灵敏度及特异度均比FIB-4高很多，表明APRI与免疫耐受期具有较高的相关性，对免疫清除期具有较高的诊断效能，诊断价值较FIB-4、GPR高。同样APRI在诊断再活动期时表现出了极高的诊断价值，而在诊断肝硬化期时，APRI的诊断效能明显低于免疫耐受期及免疫清除期，敏感度仅有65.1%，表明APRI在肝纤维化程度较低时更能表现出诊断价值，在预测肝脏炎症活动时的肝纤维化程度更敏感，而对肝硬化的诊断效能与肝炎期相比相对较弱。在诊断肝硬化期时，APRI、FIB-4、GPR、RPR的AUROC数值均在0.7以上，均表现出较好的诊断效能。相比于APRI、GPR、RPR，FIB-4具有更高的诊断价值。FIB-4以1.411为截点，其灵敏度为83.1%，比另外三者均高，说明FIB-4诊断肝硬化期的误诊率低，但其诊断肝硬化期的特异度要低于另外三者，说明若FIB-41.411为截点判断肝硬化期，还是存在33%的患者存在漏诊。</p><p>综上所述，无创肝纤维化指标在CHB感染不同阶段的诊断具有较高的诊断价值，其中APRI在诊断肝脏炎症活动具有较高的灵敏度和特异度，FIB-4可对肝硬化有一定的诊断价值，虽然不能代替肝活检，但是对于疾病的初步诊断还是具有一定借鉴意义。</p></sec><sec id="s9"><title>文章引用</title><p>严美红,王亚平,刘 营,边 城. APRI、FIB-4、RPR和GPR在慢性HBV感染诊断中的意义Significance of APRI, FIB-4, RPR and GPR in the Diagnosis of Chronic HBV Infection[J]. 临床医学进展, 2020, 10(12): 3253-3262. https://doi.org/10.12677/ACM.2020.1012487</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39516-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shiha, G., et al. (2017) Asian-Pacific Association for the Study of the Liver (APASL) Consensus Guidelines on Invasive and Non-Invasive Assessment of Hepatic Fibrosis: A 2016 Update. Hepatology International, 11, 1-30.</mixed-citation></ref><ref id="hanspub.39516-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王麟, 等. 2015年欧洲肝病学会与拉丁美洲肝病学会无创检查评估肝脏疾病严重程度及预后临床指南要点[J]. 中华肝脏病杂志, 2015, 23(7): 488-492.</mixed-citation></ref><ref id="hanspub.39516-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王贵强, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 肝脏, 2019, 24(12): 6-27.</mixed-citation></ref><ref id="hanspub.39516-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Razavi-Shearer, D., et al. (2018) Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study. The Lancet Gastroenterology and Hepatology, 3, 383-403.  
&lt;br&gt;https://doi.org/10.1016/S2468-1253(18)30056-6</mixed-citation></ref><ref id="hanspub.39516-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.M. and Banini, B.A. (2019) Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options in Gastroenterology, 17, 271-291. &lt;br&gt;https://doi.org/10.1007/s11938-019-00236-3</mixed-citation></ref><ref id="hanspub.39516-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chang, T.-T., et al. (2010) Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B. Hepatology, 52, 886-893.</mixed-citation></ref><ref id="hanspub.39516-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Schiff, E.R., et al. (2011) Long-Term Treatment with Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 9, 274-276.e1.  
&lt;br&gt;https://doi.org/10.1016/j.cgh.2010.11.040</mixed-citation></ref><ref id="hanspub.39516-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">孔媛媛, 等. 慢性乙型肝炎患者肝脏硬度值下降趋势与肝纤维化逆转结局的关系[J]. 临床肝胆病杂志, 2020, 36(2): 76-80.</mixed-citation></ref><ref id="hanspub.39516-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shihua, G., Ibrahim, A., Helmy, A., et al. (2016) An Excerpt of Asian-Pacific Association for the Study of the Liver (APASL) Consensus Guidelines on Invasive and Non-Invasive Assessment of Hepatic Fibrosis. Journal of Clinical Hepatology, 11, 1-30.</mixed-citation></ref><ref id="hanspub.39516-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., et al. (2017) American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology, 152, 1544-1577. &lt;br&gt;https://doi.org/10.1053/j.gastro.2017.03.016</mixed-citation></ref><ref id="hanspub.39516-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Teshale, E., et al. (2015) APRI and FIB-4 Are Good Predictors of the Stage of Liver Fibrosis in Chronic Hepatitis B: The Chronic Hepatitis Cohort Study (CHeCS). Journal of Viral Hepatitis, 21, 917-920.  
&lt;br&gt;https://doi.org/10.1111/jvh.12279</mixed-citation></ref><ref id="hanspub.39516-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.W., et al. (2016) Red Cell Volume Distribution Width-to-Platelet Ratio in Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B. Liver International, 36, 24-30. &lt;br&gt;https://doi.org/10.1111/liv.12868</mixed-citation></ref><ref id="hanspub.39516-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y.-C., et al. (2017) Value of Gamma-Glutamyltranspeptidase-to-Platelet Ratio in Diagnosis of Hepatic Fibrosis in Patients with Chronic Hepatitis B. World Journal of Gastroenterology, 23, 7425-7432.  
&lt;br&gt;https://doi.org/10.3748/wjg.v23.i41.7425</mixed-citation></ref><ref id="hanspub.39516-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lemoine, M., et al. (2016) The Gamma-Glutamyl Transpeptidase to Platelet Ratio (GPR) Predicts Significant Liver Fibrosis and Cirrhosis in Patients with Chronic HBV Infection in West Africa. Gut, 65, 1369-1376.  
&lt;br&gt;https://doi.org/10.1136/gutjnl-2015-311133</mixed-citation></ref><ref id="hanspub.39516-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张晶巧, 等. 《2018年美国肝病学会乙型肝炎指引声明意见: 慢性乙型肝炎的预防, 诊断和治疗》摘译[J]. 临床肝胆病杂志, 2018, 34(4): 64-69.</mixed-citation></ref><ref id="hanspub.39516-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">廖雪姣, 等. 637例慢性HBV感染者自然史各期肝组织纤维化演变规律研究[J]. 中国肝脏病杂志: 电子版, 2014(2): 1-5.</mixed-citation></ref><ref id="hanspub.39516-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">徐洪海, 郜玉峰. King指数无创诊断慢性HBV感染患者肝纤维化程度的预测价值[J]. 安徽医学, 2020, 41(5): 505-509.</mixed-citation></ref></ref-list></back></article>